BIRC5 and neoplasm: This novel system was used for the co-delivery of doxorubicin (Dox) and Survivin CRISPR/Cas9-expressing plasmid deoxyribonucleic acid (sgSurvivin pDNA), aiming to down-regulate the expression of Survivin (involved in the inhibition of apoptosis of tumour cells) and enhance the effect of the chemotherapeutic agent, Dox [50].